Promoters can contribute to the elucidation of protein function

Trends in Biotechnology

Volumn 21, Issue 1, 2003, Pages 9-13

  Werner, Thomas ^a,b  

^a Genomatix GmbH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; MAPS; PROTEINS;

TRANSCRIPTIONAL COREGULATION;

BIOTECHNOLOGY;

INTERLEUKIN 1; INTERLEUKIN 9; TUMOR NECROSIS FACTOR; PROTEIN; PROTEIN S; TUMOR NECROSIS FACTOR ALPHA;

BIOTECHNOLOGY; PROTEIN;

GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; ANIMAL; BIOLOGICAL MODEL; BIOTECHNOLOGY; CHEMISTRY; GENETIC PROCEDURES; GENETICS; GENOME; METABOLISM; METHODOLOGY; PROTEIN BINDING;

ANIMALS; BIOTECHNOLOGY; GENETIC TECHNIQUES; GENETICS; GENOME; HUMANS; INTERLEUKIN-1; INTERLEUKIN-9; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN S; PROTEINS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037212661     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)00003-3     Document Type: Article

References (36)

1. Marshall T., Williams K.M. Proteomics and its impact upon biomedical science. Br. J. Biomed. Sci. 59:2002;47-64.
2. Hanash S.M., et al. Identification of novel targets for cancer therapy using expression proteomics. Leukemia. 16:2002;478-485.
3. Hutter G., Sinha P. Proteomics for studying cancer cells and the development of chemoresistance. Proteomics. 1:2001;1148-1233.
4. Latham K.E., Schultz R.M. Embryonic genome activation. Front. Biosci. 6:2001;D748-D759.
5. Mattick J.S., Gagen M.J. The evolution of controlled multitasked gene networks: the role of introns and other noncoding RNAs in the development of complex organisms. Mol. Biol. Evol. 18:2001;1130-1611.
6. Davy A., et al. A protein-protein interaction map of the Caenorhabditis elegans 26S proteasome. EMBO Rep. 2:2001;821-828.
7. Wojcik J., Schachter V. Protein-protein interaction map inference using interacting domain profile pairs. Bioinformatics. 17:(Suppl. 1):2001;S296-S305.
8. Matthews L.R., et al. Identification of potential interaction networks using sequence-based searches for conserved protein-protein interactions or 'interologs'. Genome Res. 11:2001;2120-2126.
9. Lehman J.J., Kelly D.P. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin. Exp. Pharmacol. Physiol. 29:2002;339-345.
10. O'Shea J.J., et al. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 109:(Suppl.):2002;S121-S131.
11. Kahn A. Transcriptional regulation by glucose in the liver. Biochimie. 79:1997;113-118.
12. Werner T. Cluster analysis and promoter modelling as bioinformatics tools for the identification of target genes from expression array data. Pharmacogenomics. 2:2001;25-36.
13. Staudt L.M. Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. 53:2002;303-318.
14. Wykoff C.C., et al. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found. Symp. 240:2001;212-231.
15. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat. Rev. Immunol. 2:2002;162-174.
16. Attwood J.T., et al. DNA methylation and the regulation of gene transcription. Cell. Mol. Life Sci. 59:2002;241-257.
17. Bode J., et al. Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. Int. Rev. Cytol. 162A:1995;389-454.
18. Muyrers-Chen I., Paro R. Epigenetics: unforeseen regulators in cancer. Biochim. Biophys. Acta. 1552:2001;15-26.
19. Werner T. Models for prediction and recognition of eukaryotic promoters. Mamm. Genome. 10:1999;168-175.
20. Le Page D., et al. Interferon activation and innate immunity. Rev. Immunogenet. 2:2000;374-386.
21. Rao A., et al. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:1997;707-747.
22. de Martin R., et al. The NF-κB/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat. Res. 437:1999;231-243.
23. Kel O.V., et al. A compilation of composite regulatory elements affecting gene transcription in vertebrates. Nucleic Acids Res. 23:1995;4097-4103.
24. Heinemeyer T., et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 26:1998;362-367.
25. Klingenhoff A., et al. Functional promoter modules can be detected by formal models independent of overall nucleoside sequence similarity. Bioinformatics. 15:1999;180-186.
26. Klingenhoff A., et al. Regulatory modules shared within gene classes as well as across gene classes can be detected by the same in silico approach. In Silico Biol. 2:2002;S17-S26.
27. Gailus-Durner V., et al. Experimental data of a single promoter can be used for in silico detection of genes with related regulation in the absence of sequence similarity. Mamm. Genome. 12:2001;67-72.
28. Cassimeris L., Spittle C. Regulation of microtubule-associated proteins. Int. Rev. Cytol. 210:2001;163-226.
29. Zhou Y., et al. Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir. Res. 2:2001;80-84.
30. Schmitt E., et al. IL-1 serves as a secondary signal for IL-9 expression. J. Immunol. 147:1991;3848-3854.
31. Gounni A.S., et al. IL-9 expression by human eosinophils: regulation by IL-1β and TNF-α J. Aller. Clin. Immunol. 106:2000;460-466.
32. Fessele S., et al. Regulatory context is a crucial part of gene function. Trends Genet. 18:2002;60-63.
33. Huber C., et al. Tumor necrosis factor-α effects on rat gastric enterochromaffin-like cells. Digestion. 65:2002;87-102.
34. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. 184:2001;258-274.
35. Robinson D., et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity. 7:1997;571-581.
36. Coclet-Ninin J., et al. Interferon-β not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw. 8:1997;339-345.